ClinicalTrials.gg
CompletedNCT06005038Updated Nov 18, 2026

CogT pSOPT Intervention Study

A Phase 1 interventional study of pSOPT and MLA in Mild Cognitive Impairment and Subjective Cognitive Impairment, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Stanford University · Phase 1, Interventional, and Prevention

How we know

Updated Nov 18, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Cognitive Dysfunction by Stanford University — 3 open to participants now, 7 under way, none of them phase 3. Cognitive Dysfunction · Stanford University.

Started
2024
with 4 others
Phase 1
Only one
of the 14
Registered
8th of 14
by date

Among the 14 studies in Cognitive Dysfunction by Stanford University, this one is one of 5 that started in 2024, is the only one in phase 1, and was the 8th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

3 of the 14 studies in Cognitive Dysfunction by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Cognitive Dysfunction by Stanford University, or all of them as a file.
02

Study summary

(JUSTIFICATION: This is the R33 stage of an NIH funded R21/R33 study. R21 stage (IRB-61727) was focused on intervention development; R33 stage will focus on pilot testing the effect of the intervention. The R21 phase was not considered a NIH defined clinical trial; R33 will be considered a NIH defined clinical trial)

The purpose is to develop and test the effect of a "personalized" computer-based cognitive training program. The personalized program tailors the difficulty of the training tasks using a participant's biofeedback (i.e., heart rate) and cognitive performance. Such a personalization will ensure that the participant can perform at his/her ideal training capacity. Participants will be randomized into one of 2 groups and each group will play a different version of computerized training game and have ECG collected to allow subject blinding.

03

Conditions studied

  • Mild Cognitive Impairment
  • Subjective Cognitive Impairment
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. criteria related to defining "mild cognitive impairment": a. Presence of memory complaint; b. Rey Auditory Verbal Learning Test delayed recall (for memory) \< 59% of age-adjusted norm; c. (for global cognition) ranged 18 and 27; d. Functional Assessment Questionnaire (for activities of daily living) \< 20.
  2. intact score for San Diego Brief Assessment of Capacity to Consent (UBACC).
  3. if a participant is on AD medication (i.e., memantine, cholinesterase inhibitors, amyloid antibodies), antidepressants, anxiolytics, or vascular risk or diseases related medications (e.g., beta-blocker), the dose should be stable for 3 months prior to recruitment.
  4. age 60+,
  5. read and understand English
  6. adequate visual and hearing acuity for testing by self-report,
  7. community-dwelling (including independent living).

Exclusion criteria

Exclusion Criteria:

  1. current enrollment in another cognitive improvement study;
  2. uncontrollable major depression;
  3. major cerebrovascular and cardiovascular diseases (e.g., congestive heart failure, pacemaker, prior myocardial infarction);
  4. having an active legal guardian (indicating impaired capacity for decision making);
  5. currently pregnant
  6. 3T MRI
  7. Neurological conditions: Neurodegenerative disease diagnosis such as Parkinson's, Alzheimers, dementia, multiple sclerosis. Of note, other neurological conditions/injury such as stroke, seizures, traumatic brain injury, will be evaluated for inclusion/exclusion on a case-by-case basis based on event recency, severity, and recovery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    pSOPT

    personalized cognitive training with a close-loop parasympathetic nervous system monitored component

    Behavioral: pSOPT

  • Placebo comparator
    MLA

    computerized mental leisure activities

    Behavioral: MLA

Interventions

  • BehavioralpSOPT

    computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)

  • BehavioralMLA

    computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.

06

What researchers measure

Primary outcomes

  1. composite cognitive measure

    a composite score of episodic memory and executive function. Episodic memory will be assessed using the Rey Auditory Verbal Learning and Brief Visuospatial Memory tests. Alternative forms of the tests will be used to reduce practice effects.The Z-transform scores across all assessment points within each test will be developed first to derive 2 composite scores (learning and delayed recall). Executive function will be measured using the EXAMINER, a computerized test package designed for RCTs. It includes 8 tests and calculates 4 sub-domain composite scores on working memory (Dot counting and N-back), inhibition (Flanker, Continuous Performance Test, and Anti-saccades), cognitive control (Dimensional Set Shifting), and Fluency (Phonemic Fluency and Category Fluency), and an overall composite score for executive function. A composite score synthesizing EXAMINER composite score, learning, and delayed recall will be created; higher indicates better performance.

    Time frame: Baseline, Week 7, and 3-month

Secondary outcomes

  1. central autonomic network (CAN) functional integrity

    BOLD during resting-state will be collected using a gradient echo-planar imaging sequence. The functional scans will be acquired using simultaneous multi-slice at sub-second TRs. An in-scanner camera will be used to ensure compliance. Identification of CAN involved networks for the study: a functional network template along with 268 ROIs described previously will be used. In this functional template, CAN related networks will be focused, including SN, DMN, subcortical network, and frontoparietal networks, along with ACC subregions. The data will be analyzed using the FSL software packages. fMRI preprocessing will consist of motion correction, slice-timing correction, normalization, and Gaussian spatial smoothing (FWHM 8mm). To calculate resting-state and task-related fMRI, the correlation coefficient between ROI pair across the time course will be Fisher Z-transformed and averaged to derive summary scores for network strength; higher indicates stronger network strength.

    Time frame: Baseline, Week 7, and 3-month

07

Study locations

1 site
  • CogT Lab, Stanford University
    Palo Alto, California 94304-0000, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jun 2026, 29 months.

Of 54 non-industry phase 1 interventional studies under Cognitive Dysfunction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's 29 months is below that.

Counting every sponsor, half of 80 studies reached it within 29 months; a quarter within 13 and three quarters within 49.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2026 → Jun 2026 and completion Dec 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2023
First posted
Aug 22, 2023
StartActual
Jan 12, 2024
Primary completionActual
Jun 30, 2026was Dec 2026
CompletionActual
Jul 31, 2026was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Primary completion
Dec 1, 2026→Jun 30, 2026 (actual)
Nov 18, 2026
Study completion
Dec 31, 2026→Jul 31, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    Primary completion Dec 1, 2026→Jun 30, 2026 (now actual)
    Study completion Dec 31, 2026→Jul 31, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06005038
Responsible party
Feng Lin (Clinical Professor, Stanford University) — Principal investigator
First posted
Aug 22, 2023
Start date
Jan 12, 2024
Primary completion
Jun 30, 2026
Completion
Jul 31, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion